View More Recent Stories

Jan 13, 2025 12:50PM RBC Capital Explores Biotech Implications Following Cavazzoni's Departure from the FDA
Jan 10, 2025 01:26PM Axsome Therapeutics (AXSM) PT Raised to $180 at Truist Securities
Jan 2, 2025 01:02PM Piper Sandler Highlights NBIX, ITCI, ALKS, AXSM as High Conviction Ideas in Biotechnology
Dec 31, 2024 06:37AM Axsome Therapeutics (AXSM) PT Raised to $124 at Cantor Fitzgerald
Dec 31, 2024 06:32AM H.C. Wainwright Reiterates Buy Rating on Axsome Therapeutics (AXSM)
Dec 31, 2024 06:09AM Axsome Therapeutics (AXSM) PT Lowered to $122 at Mizuho
Dec 30, 2024 11:37PM Baird Reiterates Outperform Rating on Axsome Therapeutics (AXSM)
Dec 30, 2024 03:00PM Leerink Partners Reiterates Outperform Rating on Axsome Therapeutics (AXSM)
Dec 30, 2024 01:20PM Axsome Therapeutics (AXSM) call put ratio 1.2 calls to 1 put as share price down 6.4%
Dec 30, 2024 12:30PM Guggenheim Reiterates Buy Rating on Axsome Therapeutics (AXSM)
Dec 30, 2024 07:01AM Axsome Therapeutics (AXSM) Announces Successful Completion and Results of Phase 3 Clinical Program of AXS-05 in Alzheimer’s Disease Agitation
Dec 21, 2024 10:00AM RBC report: Biotech faces both uncertainty and growth opportunities in 2025
Dec 19, 2024 11:16AM RBC Capital's Game Changers: 'Disruptive Forces in Biotech'
Dec 16, 2024 07:03AM RBC Capital's Global Biotech Outlook Report: 'Top 2025 Ideas'
Dec 3, 2024 06:39AM Axsome Therapeutics (AXSM) PT Raised to $124 at Mizuho
Nov 26, 2024 07:00AM Axsome Therapeutics (AXSM) Announces AXS-12 Achieves Primary Endpoint
Nov 25, 2024 06:43AM H.C. Wainwright Reiterates Buy Rating on Axsome Therapeutics (AXSM)
Nov 13, 2024 06:44AM Axsome Therapeutics (AXSM) PT Raised to $132 at RBC Capital
Nov 12, 2024 01:28PM Axsome Therapeutics (AXSM) PT Raised to $135 at Guggenheim
Nov 12, 2024 01:17PM Truist Securities Reiterates Buy Rating on Axsome Therapeutics (AXSM)
Nov 6, 2024 05:53AM Here's the updated Mizuho's Top Picks List
Oct 8, 2024 06:48AM Mizuho Reiterates Outperform Rating on Axsome Therapeutics (AXSM)
Oct 1, 2024 06:47AM Wells Fargo Offers 10 High-Conviction Long/Short Ideas for Q4, Comments on tesla (TSLA): 'We see declining delivery growth'
Sep 23, 2024 07:04AM Mizuho Reiterates Outperform Rating on Axsome Therapeutics (AXSM)
Sep 16, 2024 08:43AM TD Cowen Reiterates Buy Rating on Axsome Therapeutics (AXSM)
Sep 11, 2024 06:35AM Mizuho Reiterates Outperform Rating on Axsome Therapeutics (AXSM)
Sep 10, 2024 02:27PM Axsome Therapeutics (AXSM) spreader active in January 50 and 90 puts as share price near upper end of range
Sep 5, 2024 06:48AM H.C. Wainwright Reiterates Buy Rating on Axsome Therapeutics (AXSM)
Sep 4, 2024 07:01AM Axsome Therapeutics (AXSM) Announces FDA Acceptance of NDA Resubmission for AXS-07
Sep 3, 2024 06:35AM Wells Fargo Starts Axsome Therapeutics (AXSM) at Overweight
Aug 23, 2024 11:30AM Morgan Stanley Reiterates Overweight Rating on Axsome Therapeutics (AXSM)
Aug 6, 2024 06:42AM Axsome Therapeutics (AXSM) PT Lowered to $130 at RBC Capital
Aug 6, 2024 06:40AM Axsome Therapeutics (AXSM) PT Lowered to $180 at H.C. Wainwright
Aug 6, 2024 06:12AM BofA Securities Upgrades Axsome Therapeutics (AXSM) to Buy
Aug 5, 2024 07:03AM Axsome Therapeutics (AXSM) Misses Q2 EPS by 36c, offers guidance
Jul 22, 2024 06:25AM RBC Capital Reiterates Outperform Rating on Axsome Therapeutics (AXSM)
Jul 8, 2024 03:20PM Axsome Therapeutics (AXSM) August 90, January 100 and January 125 calls active
Jun 12, 2024 02:47PM Citi Reiterates Buy Rating on Axsome Therapeutics (AXSM)
Jun 11, 2024 03:01PM Guggenheim Defends Axsome Therapeutics (AXSM), 'short report has put unnecessary pressure on the stock'
Jun 11, 2024 09:30AM Axsome Therapeutics (AXSM) new short at Culper Research
Mar 17, 2024 08:00PM Top pharma stocks to own in 2024 – Citi
View More Recent Stories